Generating durable humoral immunity through vaccination depends upon effective interaction of follicular 42 helper T cells (T fh ) with germinal center (GC) B cells. T h 1 polarization of T fh cells is an important process 43 shaping the success of T fh -GC B cell interactions by influencing co-stimulatory and cytokine-dependent T fh help 44 to B cells. However, the question remains whether adjuvant-dependent modulation of T fh cells enhances HIV-1 45 vaccine-induced anti-Envelope (Env) antibody responses. We investigated whether an HIV-1 vaccine platform 46 designed to increase the number of T h 1-polarized T fh cells enhances the magnitude and quality of anti-Env IgG titers with greater cross-clade reactivity, specificity to V1V2, and effector functions when compared to 50 macaques primed with DNA lacking IP-10 and boosted with MPLA+alum-adjuvanted Env protein (DP ALFA ) The 51 D IP-10 P ALFQ vaccine regimen elicited higher anti-Env IgG1 and lower IgG4 antibodies in serum, showing for the 52 first time that adjuvants can dramatically impact the IgG subclass profile in macaques. The D IP-10 P ALFQ regimen 53 also increased vaginal and rectal IgA antibodies to a greater extent. Within lymph nodes, we observed 54 augmented GC B cell responses and promotion of T h 1 gene expression profiles in GC T fh cells. The frequency 55 of GC T fh cells correlated with both the magnitude and avidity of anti-Env serum IgG. Together, these data 56 suggest that adjuvant-induced stimulation of T h 1-T fh cells is an effective strategy for enhancing the magnitude 57 and quality of anti-Env antibody response.
antibodies. Utilizing a novel interferon-induced protein (IP)-10-adjuvanted HIV-1 DNA prime, followed by an INTRODUCTION 5 Based on evidence that T h 1-polarized T fh cells correlate with higher antibody responses, we set out to 153 investigate empirically whether an HIV-1 vaccine platform designed to increase the number of T h 1-polarized T fh 154 cells would enhance the functional quality and magnitude of HIV-1 anti-Env antibodies.
156
Utilizing a novel interferon-induced protein (IP)-10-adjuvanted HIV-1 DNA prime, followed by an To confirm that the D IP-10 P ALFQ vaccine regimen induced relatively higher T h 1-biased inflammatory responses, 219 we evaluated induction of CXCR3 ligands in serum using a flow-based Legend plex assay at days 0, 3, and 7 220 after the 1 st protein boost. The data showed higher relative induction of IP-10 and the interferon-inducible T cell 221 alpha chemoattractant (I-TAC) in the ALFQ-adjuvanted animals (p< 0.01, Figure 1E ). Monokine induced by 222 gamma, another CXCR3 ligand, was not induced following the 1 st protein boost in either vaccine regimen (data 223 not shown). We also observed significant induction of IL-6 following the ALFQ protein boost. Induction of the 224 chemokine regulated upon activation, normal T cell expressed, and secreted (RANTES) in both vaccine groups 225 indicated presence of activated CD4 and CD8 T cells following vaccination. In all, these data showed higher 226 relative magnitude of T h 1 chemokines in the D IP-10 P ALFQ vaccine regimen. 227 228 D IP-10 Protein ALFQ vaccine induces robust and durable anti-Env antibody titers with cross-clade breadth.
229
To ascertain whether induction of greater magnitude T h 1 inflammatory responses elicited anti-Env antibody 230 responses of different magnitudes between the vaccine regimens, we first evaluated responses against C.1086 231 gp140 Env using a binding antibody multiplex assay (BAMA) (22) . We have previously shown that the transient 232 extrafollicular plasmablast response contributes to peak serum IgG antibody titers following the boost, while 233 titers at week 8 and beyond are mainly plasma cell derived (12) . Therefore, we assessed antibody levels at 234 weeks 0, 2, and 8 following each of the protein boosts to capture both extrafollicular (week 2) and plasma cell-8 fold increase at week 2 post-2 nd protein immunization relative to week 0 indicating a successful booster 245 response. In affirmation of the BAMA data, antibody titers were significantly higher in the D IP-10 P ALFQ 246 group compared to the DP ALFA group at all time points post the 2 nd protein boost.
248
We next assessed the breadth of the serum IgG antibody response and found that AUC values against CH505 249 subtype C Env were also significantly higher in the D IP-10 P ALFQ group relative to the DP ALFA group (p< 0.01, 250 Figure 2C) . Similarly, increased responses against the Con S (group M consensus) and Con C proteins at 251 week 2 following the 2 nd protein boost in the D IP-10 P ALFQ group were sustained at week 8 demonstrating greater 252 induction of antibodies with cross-clade breadth using the D IP-10 P ALFQ vaccine regimen (p< 0.05, Figure 2D ,E).
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( Figure 2) , SPR-based IgG measurements, expressed as relative units, showed significantly higher gp140 IgG 273 in the D IP-10 P ALFQ vaccine group (p< 0.0001, Figure 3C ). Therefore, we normalized avidity measurements to 274 gp140 binding measurements and observed increased avidities in the D IP-10 P ALFQ vaccine group relative to the 275 DP ALFA group, which was suggestive of more productive GC reaction in the D IP-10 P ALFQ vaccine group (p< 276 0.0001, Figure 3C ). To confirm that higher avidity antibodies in the D IP-10 P ALFQ vaccine group were sustained,
277
we determined avidity at 8 weeks following the 2 nd protein boost using a 2M sodium thiocyanate displacement 278 ELISA with C.1086C gp140 antigen(12). The data showed sustained induction of higher avidity antibodies in 279 the D IP-10 P ALFQ group (p< 0.05, Figure 3D ), which was further corroborated with a 0.1 M sodium citrate ELISA 280 (p< 0.01, Figure 3E ). Notably, higher avidity antibodies against Con C and Con S gp140 proteins were also 281 induced in the D IP-10 P ALFQ vaccine regimen (p< 0.01, Figure 3F ,G).
283
After establishing induction of higher avidity antibodies in the D IP-10 P ALFQ vaccine group, we next evaluated 284 capacity of immune sera to neutralize HIV-1 using the classic TZM-bl assay(12). We detected robust activity 285 against MW965.26, a subtype C tier 1A variant ( Figure 3H) whereas neutralization of tier 1B and tier 2 isolates 286 was sporadic (data not shown)(24). The data showed higher induction of tier 1A neutralizing antibodies in the 287 D IP-10 P ALFQ vaccine group (ID50 range at week 2 post 2 nd protein boost DP ALFA : 37 -1126; D IP-10 P ALFQ : 195-288 4977, p < 0.01). These titers dropped to an ID50 value of 20 in the DP ALFA group but were maintained between 289 24-1057 in the D IP-10 P ALFQ group (p< 0.001). To assess generation of Fc-mediated antibody effector 290 responses, we measured antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent week 8 after the 2 nd protein boost when compared to DP ALFA immunized animals (p< 0.01). Serum collected 296 from D IP-10 P ALFQ vaccinated animals at week 8 post protein boost 2 also mediated significantly greater 297 phagocytosis of C.1086 gp120-coated beads by the CD32+ (FcR2) and CD64+ (FcR1) THP-1 monocytic cell 298 line (Figure 3J and K) . To determine if the adjuvants given to animals in the vaccine groups generated 10 IgG4 by ELISA. We found that IgG2 and IgG3 antibodies were extremely low and did not differ between groups 301 ( Figure 3L ). However, D IP-10 P ALFQ vaccinated animals had higher gp120-specific IgG1 (p< 0.0001, Figure 3L ) 302 while DP ALFA vaccinated animals had higher gp120-specific IgG4 resulting in markedly elevated IgG1/IgG4 303 ratio in the D IP-10 P ALFQ vaccine group (p< 0.001, Figure 3M ). The IgG4 detection antibody (clone 78A) showed 304 minimal cross-reactivity to IgG1 and IgG3 subclass antibodies indicating specificity of the antibody to rhesus than the DP ALFA regimen for generating higher magnitude Env binding antibodies in serum and secretions, as 329 well as serum IgG antibodies with greater breadth, avidity, and function.
331
Next, we determined whether the relatively higher antibody concentrations of anti-gp140 antibody in mucosal 332 secretions in the D IP-10 P ALFQ vaccine group might result in delayed acquisition against the Clade C 333 transmitted/founder virus, SHIV.C.CH505. To this end, we challenged monkeys intra-vaginally with eight 334 repeat, low-dose inoculations of SHIV.C.CH505 at week 20 post the 2 nd protein boost. While we observed no 335 significant differences in delay in acquisition between the vaccine groups, 3 of 10 animals in the D IP-10 P ALFQ 336 vaccine group were protected relative to 0 of 10 animals in DP ALFA regimen ( Figure 4F ). We observed that 337 mucosal gp140 IgG antibody concentrations at week 16 post 2 nd protein boost was a correlate of protection, 338 with higher concentrations correlating with delayed acquisition in infected animals in each of the vaccine 339 groups (r = 0.94, p < 0.01; D IP-10 P ALFQ vaccine group, n = 7; r = 0.78, p < 0.01; DP ALFA vaccine group, Figure   340 4G).
D IP-10 Protein ALFQ vaccine induces Env-specific T fh cells and GC T fh cells with distinctive T h 1 signatures.

342
The D IP-10 P ALFQ vaccine promoted anti-Env antibody magnitude and functionality following the 1 st protein boost.
343
Based upon this finding, we wanted to determine whether this vaccine regimen also correspondingly enhanced 344 T fh cells in the periphery and LNs. To this end, we first assessed whether higher frequencies of Env-specific T fh 345 cells were induced in blood 7 days after the 1 st protein boost, corresponding to the peak of the effector 346 response. PBMCs were stimulated with overlapping peptide pools representing Con C gp140 together with the 347 HIV-1 C.1086 Env gp140C protein C. The induction of the activation markers CD25 and OX40 was assessed 348 by flow cytometry after stimulation (Figure 5A , flow plot)(30). The analysis revealed a higher frequency of Env-349 specific CD4 T cells in the circulation of D IP-10 P ALFQ animals. When expressed as a percentage of CD95 + CD4 T 350 cells, median frequencies of Env specific-CD4 T cells were on average 10-fold higher in the D IP-10 P ALFQ group 351 indicative of a higher magnitude Env-specific T fh response (p < 0.001, Figure 5B ). In all, these data showed 352 robust recall responses following the 1 st protein boost with higher relative magnitude of Env-specific T fh cells in 353 the D IP-10 P ALFQ vaccine regimen.
12
Next, we assessed LN responses using biopsies collected at day 14 post 1 st protein boost and identified GC T fh 355 cells as CXCR5 + , PD-1 +++ cells (red population, Figure 6A ) and GC B cells as Ki-67 + , Bcl-6 + CD20 cells. As 
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While frequencies of GC T FH cells were not significantly different between experimental groups, we found that 362 GC B cell frequencies were significantly higher in the D IP-10 P ALFQ vaccine regimen (n=10 animals in each group 363 following the 1 st protein boost; median DP ALFA : 14.2% (of CD20 + cells) versus D IP-10 P ALFQ : 25%, p < 0.05 and 364 the frequency of GC T fh cells strongly correlated with GC B cell responses ( Figure 6D) . Importantly, Env-365 specific T fh cell frequencies in the LN directly correlated with GC T fh cell frequencies but not memory T fh cells 366 indicating that GC T fh cells were enriched for vaccine-induced follicular cells (p<0.0001, Figure 6D ). Next, we 367 assessed expression of CXCR3, which is heterogeneously expressed by GC T fh cells ( Figure 6E ) and found 368 higher expression of CXCR3 on GC T fh cells in the D IP-10 P ALFQ group. We observed that the frequency of 369 CXCR3 + T fh cells within the GC was directly associated with gp140 serum antibody titers at week 18 post 2 nd 370 protein boost (r =0.44, p < 0.05; Figure 6E ). Examination of GC B cells showed elevated CXCR3 expression in 371 GC B cells from the D IP-10 P ALFQ vaccine group (p< 0.05, Figure 6F) . Notably, T-bet expression on B cells, a 372 marker of memory B cells (31), corresponded with CXCR3 expression, suggesting a mechanistic basis for 373 enhanced antibody responses in the D IP-10 P ALFQ vaccine group. Together, these data support the contention 374 that T h 1 skewing of CD4 T fh cells may support higher anti-Env antibody.
376
To gain insights into the molecular mechanisms underlying successful antibody responses we next determined 377 transcriptional signature in GC T fh cells. To achieve this goal, we sorted naive CD4 cells, CD4 Tfh cells, and 
397
To determine transcriptional activity of T fh cells in the D IP-10 P ALFQ vaccine group, we focused on differentially 398 induced genes in T fh cells relative to naive cells (n=89, adj. p < 0.05, Figure 6G) , of which induction of key T fh 399 transcripts including CXCR5, ICOS, and Bcl-6 was common to both T fh cells and memory T fh cells. Heatmap 400 shows expression of genes differentially expressed in T fh cells relative to naive across four sorted CD4 401 subsets. Consistent with representation of D IP-10 P ALFQ genes in GSEA, T fh cells showed higher expression of 402 TBX21 and IFNG (Figure 6G,H) . The class IV semaphorin protein (SEMA4A), a co-stimulatory molecule 403 expressed by D IP-10 P ALFQ cells(33) was significantly induced as was high-mobility group box 1 (HMGB1), an 404 inflammatory mediator regulating TNF and IL-6 production (34). Induction of IL-18R suggested the capacity of 405 IL-18 to drive IFNG production within the GC(35). Likewise, we noted higher expression of receptor interacting 406 serine/threonine kinase 2 (RIPK2) which drives IFNG in T h 1 cells and contributes to T h 1 differentiation (36) .
407
The corresponding downregulation of IL-4R in T fh cells indicated enrichment of the T h 1 program within T fh cells 14 in D IP-10 Pro ALFQ vaccinated animals. This together with increased protein expression of CXCR3 within the GC 409 suggested that CD4 T cell help for humoral immunity was driven by T h 1 T fh cells in the D IP-10 P ALFQ vaccine 410 regimen. Figure 7A) . Based on co-expression of ICOS and PD-1, activation markers induced 417 upon TCR stimulation, the data showed that DNA immunization significantly increased the relative frequencies 418 and absolute counts of ICOS + PD-1 + CXCR5 + CD4 T cells in blood at day 14 (n=20; median frequencies, day 419 0: 3.38%; day 14: 6.7%, p < 0.0001; n =20; absolute counts, day 0: 3.04; day 14, 8.7 day 14, p < 0.01, Figure   420 7A) in both experimental groups indicating that DNA delivery by electroporation was immunogenic.
422
Next, we assessed whether DNA immunization elicited humoral responses against SIV Gag and HIV Env 423 proteins expressed in the plasmid. We found that detectable responses to Gag were observed in 45% of 424 animals at week 2 of the 1 st DNA prime, in 65% at week 2 following the 2 nd DNA prime, and all animals 425 following the 3 rd DNA prime (Figure 7B , significance symbols compare immunization time points relative to 426 baseline). Antibody responses to C.1086 Env were low and undetectable until the 2 nd DNA prime (data not 427 shown), but were observed in majority of animals following DNA3 (Figure 7C , significance symbols compare 428 immunization time points relative to baseline). Gag and Env antibody titers were not significantly different 429 between the vaccine regimens during the DNA primes. Based on robust induction of anti-Gag antibody 430 responses, we determined whether Gag specific CD4 T cells were induced at week 1 following DNA3, when 431 the CD4 effector response peaked. PBMCs were stimulated with pooled SIVmac 239 Gag peptide pools and 432 interrogated for expression of activation markers (AIM) and for induction of cytokines (ICS). The AIM assay 433 captured a higher proportion of Gag-specific CD4 T cells (Figure 7D) and together, these data indicated that 434 the DNA immunization was sufficiently immunogenic to prime T and B cell responses.
Based on the induction of antibody and T cell responses following DNA3, we next assessed whether a 437 concomitant acute induction of pro-inflammatory monocytes (innate cells that drive T fh responses) preceded 438 the appearance of these cells in blood (37, 38) . We quantified frequencies of CD14 + CD16 + HLA-DR+ (lineage-
439
) cells in blood (Figure 7 E,F) and discovered rapid and robust expansion of pro-inflammatory monocytes in 440 both vaccine groups with significantly higher induction in the D IP-10 P ALFQ vaccine group (Figure 7G) . Based on 441 this, we asked if LN responses differed between vaccine groups. Strikingly, the GC T fh cell frequencies within 442 the fine-needle aspirates of the draining LN were higher in the D IP-10 P ALFQ vaccine group following the 3 rd DNA 443 immunization (Figure 7H) . Notably, the greater inflammatory response was associated with increased levels of 444 serum IgG antibodies, linking the innate immune response to priming of effective CD4 T fh help (Figure 7I) . (53). Therefore, whether increased immunogenicity detracts from protection is an important safety 545 consideration in the use of T h 1 adjuvants and other highly immunogenic vaccine platforms(46). This is 546 particularly important as the HIV co-receptor CCR5 is primarily expressed on T h 1 cells (12). Nevertheless, 547 because T h 1 cells also produce CCR5 ligands, it is important to determine frequency of T h 17 cells at the 548 mucosal portals following immunization as T h 17 cells are preferential targets of infection within the vaginal 549 mucosa(54). Another consideration is that the studies were performed on females and did not encompass the 550 possible variability in vaccine response between sexes. Therefore, going forward, it is critical to determine and 551 confirm if a T h 1 vaccine regimen will also enhance antibody responses in males.
553
In addition to adjuvant-dependent modulation of T fh responses, our IgG subclass results also support the 554 conclusion that the D IP-10 P ALFQ and DP ALFA vaccine regimens induced qualitatively different GC responses. This 555 is also the first study to show that adjuvants can dramatically impact the IgG antibody subclass profile in 556 rhesus macaques. We made the striking observation that while both vaccine regimens induced IgG1 antibodies 557 to gp120, the DP ALFA regimen generated much greater IgG4 responses. The T h 2-promoting aluminum adjuvant 558 is most likely responsible for the increased IgG4 in DP ALFA animals because both vaccine groups received ALF 559 liposomes. Rhesus IgG4 antibodies can mediate phagocytosis, but overall they appear to have poor effector 560 functions (55, 56) and the most functional IgG subclass in macaques has been reported to be IgG1 (56).
561
Humans immunized with an alum-formulated HIV-1 gp120 protein have been found to develop IgG1 and IgG4 562 but not IgG2 and IgG3 antibodies(57). However, important functional differences in IgG subclass antibodies 563 and FcR biology between non-human primates and humans (58, 59) , and the fact that rhesus IgG subclasses 564 are numbered by serum abundance not function preclude direct comparisons between species. Another 565 consideration is that differing antigen affinities between IgG subclasses to HIV-1 gp140 could confound 566 quantitation raising the possibility that subclass differences may be driven by differential affinities/epitope 567 specificities rather than differential magnitudes. Therefore, more conclusive studies are needed to evaluate 568 these possibilities. 
579
In summary, our findings demonstrate that T h 1-DNA prime substantially increases the frequency of Env-580 specific T fh cells and that T h 1-Env protein boosting results in greater production of anti-Env IgG1 antibodies 581 with enhanced magnitude, breadth, avidity, and function. How this regimen can be further optimized to 582 significantly enhance and induce robust tier 2 neutralizing antibodies is an important question that warrants 583 further study. 
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Tween 20 and blocked for 30 min at RT with reagent buffer (0.1% bovine serum albumin in wash buffer). Two-755 or three-fold dilutions of serum in reagent buffer were then added to the wells coated with gp120. Reagent 756 buffer was added to wells coated with standard. Following overnight storage at 4˚C, the plate was washed and 757 reacted for 1 h at 37˚C with 1 µg/mL of the relevant monoclonal antibody from the Nonhuman Primate Reagent 
